In melanoma elevated serum levels of MIA (Melanoma Inhibitory Activity) and S-100B (beta) are associated with shorter survival and thus were useful as prognostic factors in stages III and IV disease [4–8] and are elevated after recurrence of the disease. Here, S100B is linked to melanoma.